Quantum Genomics Corp Widens Net with Acquisition of Eurobiobiz SAS
Drug developer QGC boosts European capacity to identify and
select high potential molecules in the lab
JERSEY CITY, N.J. - October 29, 2007 - Quantum Genomics Corp.
(QGC), a global biotech company developing new drugs for metabolic
and cardiovascular diseases, announces today the acquisition of
Eurobiobiz SAS, a company specializing in the identification and
development of high value-added projects in the field of life
sciences and academic research. Financial terms were not
disclosed.
QGC's core business is the development of new drugs. In order to do
this, the company identifies research projects involving innovative
compounds with a high potential of reaching the clinic. Eurobiobiz
has developed a tried and tested evaluation method for this type of
research project and holds a unique position in Europe in this
domain. This acquisition means that a dedicated and experienced
team now joins QGC. QGC has already worked with this team for more
than a year on the evaluation of a number of scientific projects.
Bringing the two companies together will further improve this
synergy.
"Through this acquisition, QGC boosts its business development and
its ability to detect useful molecules, especially in Eastern
Europe where Eurobiobiz has particularly good connections and where
scientific resources are under-exploited," said Lionel
Ségard, chairman and CEO of QGC. "Eurobiobiz's experience of
both in- and out-licensing as well as its know-how in training
scientists Europe-wide, is a real plus for QGC and will enable us
to accelerate the development of our molecules from the scientist's
bench through to late-stage clinical trials."
"I am delighted that Eurobiobiz is adding to its capabilities by
joining QGC," said Michel Lepers, founder and director of
Eurobiobiz.
"By combining our know-how, we are creating a unique entity in
Europe which will become the privileged partner of biomedical
research in Europe, and bring to market innovative molecules
developed from academic research."
About Eurobiobiz Eurobiobiz is specialized in the identification
and management of high value-added projects in the field of life
sciences and academic research. Eurobiobiz has acquired in-depth
experience in evaluating companies, technology transfer and
training. The company organizes regular "Bio Entrepreneur Boot
Camps" in collaboration with the European Commission to encourage
the creation of innovative science-based companies.
Since the company was set up in 1999, Eurobiobiz has trained more
than 650 scientists across Europe and has been actively involved in
the creation and development phases of more than 40 biotechnology
companies, including Newron (Italy), Kibow Biotech (USA) and Aptys
Pharmaceuticals (France).
For more information go to www.eurobiobiz.com
About Quantum Genomics Corp. QGC is a biotechnology company
seeking to develop new therapies in areas where an unmet medical
need exists. QGC's focus is on metabolism-related diseases and
cardiovascular pathologies. It will co-develop some products with
academic teams and will set up strategic alliances and commercial
partnerships to cover all areas of research in life sciences.
The company is headquartered in Jersey City, New Jersey, USA. It
has a European office in France under the leadership of
Lionel
Ségard.
For more information go to www.Quantum-Genomics.com
-- --
Katie Ollerenshaw
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
katie@ala.com
Brighton Business Centre 95 Ditchling Road Brighton
BN1 4ST
ENGLAND
Tel: +44 1273 675100 Fax:
+44 1273 675400
55 rue Boissonade 75014 Paris
FRANCE
Tel: +33 1 56 54 07 00 Fax: +33
1 56 54 07 01
contact: Andrew Lloyd & Associates Andrew Lloyd / Neil
Hunter Tel: +44 1273 675100 allo@ala.com / neil@ala.com
Posted: October 2007
